Prognostic factors and outcome of ABVD chemotherapy in childhood Hodgkin Iymphoma: A single center experience

Abstract

Aim: The aim was to analyze the outcome of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vinblastine,and dacarbazine (ABVD) chemotherapy + adjuvant radiotherapy according to the risk groups and determine the adverse prognosticfactors affecting survival in Hodgkin lymphoma.Material and Methods: A retrospective study was performed on 52 pediatric patients with Hodgkin lymphoma who were treated withABVD between 1997 and 2018. Patients with early-stage favorable disease received 4 cycles of ABVD + radiotherapy. Early-stageunfavorable and advanced-stage patients received 6 cycles of ABVD + radiotherapy.Results: Thirty (57.7%) boys and 22 (42.3%) girls were included in the study. The median age of the patients was 9 years and 3months (1 year and 10 month – 17 years and 7 months). Overall survival rate was 94.2% and the mean survival time was 19.5±0.70(95% CI, 18.1 - 20.9) years. The mean event-free survival time was 9.5±6.5 years. Overall survival rate was 90%, and the meanevent-free survival time was 8.2±6.1 years in early-stage favorable disease. Overall survival rate was 100%, and the mean eventfreesurvival time was 1.9±7.0 years in early-stage unfavorable disease. Overall survival rate was 94.1 %, and the mean event-freesurvival time was 8.9±6.3 years in advanced-stage disease. Presence of bulky disease, nodular sclerosing histologic subtype andleukocytosis had a negative prognostic effect on relapse and bulky disease had adverse effect on overall survival (p